Print this page

18th annual EAHAD Congress

February has been a memorable month in terms of Werfen Participation in Scientific Events for Hemostasis.

The 18th Annual EAHAD Congress (European Association for Haemophilia and Allied Disorders) in Milan provided an excellent opportunity to explore the latest advancements in Hemophilia and Allied Disorders.

Numerous pharmaceutical companies sponsored outstanding satellite symposia, highlighting a growing interest in innovative therapies, and the high-profile joint sessions in the auditorium were attended by a large and engaged audience.

Although Werfen did not directly sponsor the event, our participation was crucial for staying abreast of emerging trends and networking with prominent speakers. This also opened doors to potentially invite some of these experts to our upcoming Scientific Seminars.

Key Highlights:

  • Comprehensive overview of the available therapies for Hemophilia, including non-factor and gene therapies.
  • Detailed review and comparison of current commercial methods for measuring FVIII/FIX activity, with a special focus on long-acting factors and non-replacement therapies.
  • Monitoring factor levels post-gene therapy.
  • Diagnosis and treatment of hereditary FX deficiency and von Willebrand Disease (vWD).
  • Hemophilia education and awareness, covering topics such as Women & Girls with Hemophilia, aging, and frailty.

EAHAD Congress1

EAHAD Congress2

EAHAD Congress4

 

EEMEA Marketing Hemostasis Team

 

Last modified on Tuesday, 24 February 2026 12:31